ジョージア州における乳がんの臨床試験
ジョージア州内の拠点で、乳がんに関する53件の研究が参加者を募集しています。
ジョージア州内の都市
- Atlanta41件の研究
- Savannah11件の研究
- South Fulton5件の研究
- Augusta5件の研究
- Athens5件の研究
- Johns Creek4件の研究
- Gainesville3件の研究
- Sandy Springs3件の研究
公式研究テキスト（英語）
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Northeast Georgia Medical Center Braselton, Braselton
- Atlanta VA Medical Center, Decatur
- Northeast Georgia Medical Center-Gainesville, Gainesville
- 他4件
被験者募集中観察研究健康なボランティア歓迎
40歳〜75歳 · 全性別 · 2026/10/02更新 · NCT05334069A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
- Winship Cancer Institute, Emory University, Atlanta
被験者募集中第2相
18歳以上 · 全性別 · 2026/10/01更新 · NCT06369285Conventionally Fractionated vs. Hypofractionated Comprehensive Nodal Irradiation for Breast Cancer Using Pencil Beam Scanning Proton Therapy
- Emory Proton Therapy Center, Atlanta
被験者募集中第3相
19歳以上 · 女性 · 2026/09/29更新 · NCT05856773A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy
- Emory University Hospital, Atlanta
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/28更新 · NCT05646862A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- City of Hope Cancer Center - Atlanta ( Site 0102), Newnan
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT06966700A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
- Archbold Memorial Hospital-Lewis Hall Singletary Oncology Center ( Site 0032), Thomasville
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT06312176The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
- Emory University Winship Cancer Institute, Atlanta
- Liberty County Cancer Care, Hinesville
- Pembroke Medical Oncology & St Joseph's/Candler Oncology Infusion Suite, Pembroke
- 他2件
被験者募集中第3相
60歳以上 · 全性別 · 2026/09/25更新 · NCT06377852Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
- Clinical Trial Site, Marietta
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/23更新 · NCT07085767A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
- Piedmont Columbus Regional - John B. Amos Cancer Center, Columbus
- Central Georgia Cancer Care, Macon
- City of Hope National Medical Center, Atlanta Cancer Center, Newnan
- 他2件
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/22更新 · NCT07174336A Study of LY4257496 in Participants With Cancer (OMNIRAY)
- Emory University School of Medicine - Winship Cancer Institute, Atlanta
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/22更新 · NCT07114601A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
- Winship Cancer Institute, Atlanta
被験者募集中第2相
18歳以上 · 女性 · 2026/09/22更新 · NCT07287098A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer
- University Cancer & Blood Center, LLC, Athens
- Winship Cancer Institute of Emory University, Atlanta
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/17更新 · NCT06827236A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
- University Blood & Cancer Center, LLC, Athens
- Winship Cancer Institute, Atlanta
- Northside Hospital, Atlanta
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/15更新 · NCT06492616Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
- Georgia Cancer Center at Augusta University, Augusta
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/10更新 · NCT06293898A Study of SDX-7320 in Combination With Eribulin for People With Breast Cancer
- Emory University (Data Collection Only), Atlanta
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/09更新 · NCT05570253A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With Early-stage and Advanced HR+ Breast Cancer
- University Cancer & Blood Center, LLC, Athens
- Summit Cancer Care, Savannah
被験者募集中第1相
18歳〜55歳 · 女性 · 2026/09/09更新 · NCT07310420A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer
- Research Site, Marietta
被験者募集中第3相
18歳〜130歳 · 全性別 · 2026/09/08更新 · NCT07647328A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
- Winship Cancer Institute of Emory University, Atlanta
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/08更新 · NCT07100106A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
- Emory University, Atlanta
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/04更新 · NCT06400472Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
- Atlanta Cancer Care - Northside Hospital, Atlanta
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/03更新 · NCT06982521Toci +/- SOC Chemo for Metastatic Triple Negative and ER-positive, HER2-negative Breast Cancers
- Emory University, Atlanta
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/03更新 · NCT05846789A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
- Northwest Georgia Oncology Centers PC - Marietta, Marietta
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/03更新 · NCT06790693Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
- Phoebe Putney Memorial Hospital, Albany
- University Cancer and Blood Center LLC, Athens
- Grady Health System, Atlanta
- 他16件
被験者募集中第3相
18歳〜60歳 · 女性 · 2026/09/02更新 · NCT05879926Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
- Winship Cancer Institute of Emory University, Atlanta
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/02更新 · NCT06072612Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
- Emory University - Winship Cancer Institute, Atlanta
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/27更新 · NCT06582017A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases
- Augusta University, Augusta
被験者募集中第2相
18歳以上 · 全性別 · 2026/08/21更新 · NCT06764940Mobile Health Patient Navigation for the Improvement of Screening and the Early Detection of Breast Cancer in Women Accessing Primary Care Clinics in Kenya
- Emory University Hospital/Winship Cancer Institute, Atlanta
被験者募集中健康なボランティア歓迎
18歳以上 · 全性別 · 2026/08/14更新 · NCT07764796Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC
- Winship Cancer Institute at Emory University, Atlanta
被験者募集中第2相
18歳以上 · 全性別 · 2026/08/12更新 · NCT06263543FIH Study of RGT-419B Alone and With Endocrine Therapy in HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer
- Emory University, Atlanta
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/12更新 · NCT05304962A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
- Northside Hospital, Atlanta
被験者募集中第2/3相
18歳以上 · 全性別 · 2026/08/10更新 · NCT06926868Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
- City of Hope - Cancer Center Atlanta, Newnan
被験者募集中第3相
18歳〜100歳 · 全性別 · 2026/08/06更新 · NCT05232916Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- Augusta University Georgia Cancer Center, Augusta
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/04更新 · NCT05579366E-Mindfulness Approaches for Living After Breast Cancer
- Grady Health System, Atlanta
- Emory University Hospital Midtown, Atlanta
- Emory University Hospital/Winship Cancer Institute, Atlanta
- 他3件
被験者募集中第3相
18歳〜50歳 · 全性別 · 2026/08/04更新 · NCT06748222Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
- Emory University, Atlanta
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/07/30更新 · NCT07288359First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
- Winship Cancer Institute, Emory University, Atlanta
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/07/07更新 · NCT05768139A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
- Winship Cancer Institute, Emory University, Atlanta
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/06/29更新 · NCT05377996A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study
- GSK Investigational Site, Atlanta
被験者募集中第2相
18歳以上 · 全性別 · 2026/06/24更新 · NCT04641247Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
- Emory University School of Medicine, Atlanta
被験者募集中第3相
18歳以上 · 全性別 · 2026/06/22更新 · NCT05696626Evaluating an Evidence-Based Family History Screening Program Adapted to Increase Reach and Uptake of Screening for BRCA-Associated Cancers in Rural Public Health Clinics
- Emory University Hospital/Winship Cancer Institute, Atlanta
被験者募集中健康なボランティア歓迎
25歳以上 · 女性 · 2026/05/26更新 · NCT06760507Evaluating and Monitoring Immune and Clinical Responses in Early-Stage Triple Negative Breast Cancer Undergoing Neoadjuvant Chemo-immunotherapy With Pembrolizumab
- Emory University/Winship Cancer Institute, Atlanta
被験者募集中観察研究健康なボランティア歓迎
18歳以上 · 女性 · 2026/05/07更新 · NCT05877859ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。